Carregant...
From Bench to FDA to Bedside: US Regulatory Trends for New Stem Cell Therapies
The phrase “bench to bedside” is commonly used to describe the translation of basic discoveries such as those on stem cells to the clinic for therapeutic use in human patients. However, there is a key intermediate step in between the bench and the bedside involving governmental regulatory oversight...
Guardat en:
| Publicat a: | Adv Drug Deliv Rev |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4398607/ https://ncbi.nlm.nih.gov/pubmed/25489841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.addr.2014.12.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|